| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.29 | 2e-08 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.25 | 4e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.23 | 9e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.23 | 0.0002 |